Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

More money comes in to further work on gene therapy for choroideremia

NightstaRx Ltd (Nightstar), a biopharmaceutical company spun out from the University of Oxford specialising in developing gene therapies for inherited retinal dystrophies, has announced that it has completed a $35 million  (£23.2 million) funding round. The round was led by New Enterprise Associates (NEA), one of the world’s leading venture capital firms. 

Nightstar’s lead programme is a gene therapy for an inherited form of progressive blindness, choroideremia, developed by Professor Robert MacLaren at Oxford’s Nuffield Laboratory of Ophthalmology, part of the Nuffield Department of Clinical Neurosciences. 

Read more...

Similar stories

Scientists uncover the role of neuronal networks in moving between wake and sleep states

Changes in the way that neurons communicate with each other affect our ability to move between sleep and wake states.

Professor Robert MacLaren receives Innovation Award

Professor Robert MacLaren is the winner of the Inspiring Leadership category in the Vice-Chancellor's Innovation Awards 2020 for his work on Nightstar, a retinal gene therapy company.

Seminar Summary: Interventions for improving chronic sleep disruption

DPhil student Lampros Bisdounis summarises a departmental seminar by Associate Professor Simon Kyle